Debu Tripathy on Monitoring Patients with Breast Cancer on Oral Oncolytics

Debu Tripathy on the management of patients with breast cancer on oral oncolytics.

Debu Tripathy, MD, Chair of Breast Medical Oncology at MD Anderson Cancer Center, discusses the important points for nurses to keep in mind when managing patients with breast cancer who are taking oral oncolytics.

The oral agents such as palbociclib (Ibrance) and everolimus (Afinitor) can come with side effects that cause patients to discontinue treatment. These are side effects such as mouth ulcers, with everolimus, and fatigue, with palbociclib. Nurses can be sure to anticipate these side effects, educate the patients on the possibilities, and monitor patients closely throughout treatment.

Related Videos
Alyssa Ridad
Yelena Shames
Johanna Garibaldi
Elizabeth Cullen
Shivani Gopalsami
Seth Eisenberg
Pattie Jakel
Kellie Zeichner
Brenda Martone
Christine Wylie
Related Content
© 2023 MJH Life Sciences

All rights reserved.